Form 4: Eli Lilly Director Acquires Shares Under Deferral Plan

Director J. Erik Fyrwald acquired 12.024 shares of Eli Lilly & Co common stock at $824.76 per share under the company's Directors' Deferral Plan.

Summary

• On March 17, 2025, J. Erik Fyrwald, a director of Eli Lilly & Co, acquired 12.024 shares of common stock.
• The shares were acquired at a price of $824.76 per share.
• This transaction increased Fyrwald's direct holdings to 72,827.098 shares.
• The acquisition was made under the Lilly Directors' Deferral Plan, with shares deferred in lieu of cash compensation and to be settled after separation from service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation.

Positives

• The acquisition of shares by a director may signal confidence in the company's future performance.

Future Outlook

The shares acquired are deferred and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

Directors' share acquisitions are common and often viewed as a positive sign, reflecting management's belief in the company's prospects. Deferral plans are also a common way to compensate directors.

Related Party Transactions

• The acquisition of shares under the Lilly Directors' Deferral Plan constitutes a related party transaction.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is part of a pre-existing compensation plan.

Key Dates

Keywords

Form 4, Director, Share Acquisition, Eli Lilly, LLY, Directors' Deferral Plan, Beneficial Ownership